Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153

Benzinga Newsdesk www.benzinga.com Neutral 66.1%

Neg 0% Neu 66.1% Pos 0%

Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.